Transparency in Reimbursement Decisions: In Whose Best Interest? Tania StafinskiDevidas Menon Commentary 28 May 2014 Pages: 725 - 727
Do Changes in Drug Coverage Policy Point to an Increased Role for Cost-Effectiveness Analysis in the USA? James D. Chambers Current Opinion 24 May 2014 Pages: 729 - 733
Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider Matt D. StevensonPeter L. Selby Practical Application 09 April 2014 Pages: 735 - 743
Economic Evaluations of Gastroesophageal Reflux Disease Medical Management Andrew J. GawronDustin D. FrenchColin W. Howden Systematic Review 08 May 2014 Pages: 745 - 758
A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis Ayse KuspinarNancy E. Mayo Systematic Review 21 May 2014 Pages: 759 - 773
Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK Alex DiamantopoulosA. FinckhF. Dejonckheere Original Research Article Open access 23 May 2014 Pages: 775 - 787
The Better than Dead Method: Feasibility and Interpretation of a Valuation Study R. A. van HoornA. R. T. DondersP. F. M. Stalmeier Original Research Article 21 May 2014 Pages: 789 - 799
A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding Rosarin SruamsiriPiyameth DilokthornsakulNathorn Chaiyakunapruk Original Research Article 22 May 2014 Pages: 801 - 813